RNA, U2 small nuclear 37, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU2-37P profile across patient tissues and cancer cell-line models. RNU2-37P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RNU2-37P is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, RNU2-37P RNA expression shows 6,717 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, BRCA, and STAD as cancer lineages where RNU2-37P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU2-37P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU2-37P survival associations across molecular data types. RNU2-37P RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU2-37P RNA expression–survival associations across cancer types. High RNU2-37P expression shows unfavorable associations in KIRP, MESO, LIHC and DLBC, but favorable associations in HNSC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for RNU2-37P RNA expression.
This table summarizes RNU2-37P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU2-37P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU2-37P shows lower tumor expression in BRCA, THCA, LUAD and KICH and higher tumor expression in CHOL. The BRCA box plot shows higher RNU2-37P RNA expression in normal versus tumor tissue (log2 FC = −0.540, t-test p = .001).
This table shows molecular features associated with RNU2-37P in patient tissues and cancer cell lines. In patient samples, RNU2-37P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
